

- In recent years defibrotide (DFT) has emerged as a promising therapy for veno-occlusive disease.
- Forty-four pediatric patients who underwent hematopoietic stem cell transplantation (HSCT) were distributed into two groups based on the use (DFT group) or non-use of prophylaxis with DFT.
- All DFT group patients received 25 mg/kg/day DFT from the first day of conditioning to day +30 after HSCT.
- Polymorphonuclear neutrophils in the DFT group had a delay to the engraftment close to 7 days, shifting from a median time to engraftment near day +14 to day +21 after HSCT.
- No increase in infection risk and transplant-related mortality was observed due to engraftment's delay during the first 30 days after HSCT.

This summary slide represents the opinions of the authors. No funding or sponsorship was received for this study or publication of this article. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).